MAPT and Alzheimer disease: Further, biomarker-based diagnosis of AD, brain imaging of amyloid plaques, and measures of the degree of tau and Aβ deposition in the cerebrospinal fluid (CSF) have been proposed as possible methods to increase the reliability of AD diagnosis.